Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Endogenous viral elements constitute a complementary source of antigens for personalized cancer immunotherapy

ABSTRACT: Endogenous viral elements constitute a complementary source of antigens for personalized cancer immunotherapy

PROVIDER: PRJNA926630 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR23194268_1.fastq.gz	Fastqsanger.gz
	SRR23194268_2.fastq.gz	Fastqsanger.gz
	SRR23194269_1.fastq.gz	Fastqsanger.gz
	SRR23194269_2.fastq.gz	Fastqsanger.gz
	SRR23194270_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 12

Similar Datasets

Endogenous viral elements constitute a complementary source of antigens for personalized cancer immunotherapy

Project description:We present a pipeline, ObsERV, for the design of personalized cancer immunotherapies based on epitopes derived from endogenous retroviral elements (EVEs). We show that EVE-derived peptides are presented as antigens on tumors and can be predicted by ObsERV. Preclinical testing of ObsERV demonstrates elicitation of poly-functional CD4+ and CD8+ T-cell responses as well as long-term tumor protection and persistence of the responses.

2025-03-26 | GSE223515 | GEO

Dendritic Cells Compare the Similarity of Endogenous and Exogenous Antigens

2007-04-12 | GSE7247 | GEO

Epigenetic therapy activates TE-chimeric transcripts to provide additional source of antigens in glioblastoma stem cells

Project description:Epigenetic treatment induces TE-chimeric antigens in glioblastoma stem cells

2024-06-05 | GSE227059 | GEO

Translation dysregulation in cancer as a source for targetable antigens.

Project description:Translation dysregulation in cancer as a source for targetable antigens.

| PRJNA1139766 | ENA

Transcription profiling of mouse dendritic cells compare the similarity of endogenous and exogenous antigens

Project description:Here we demonstrate by the use of extensive controls and stringent statistical analysis that dendritic cells differentially regulate hundreds of different genes based upon sequence similarity of endogenously- and exogenously-loaded antigens and in a T-cell independent fashion. When endogenously and exogenously-derived antigens are identical, dendritic cells upregulate many different components of the Th-1 response, favoring the priming of CD8+ effectors and promulgating cellular immunity. Experiment Overall Design: Dendritic cells were loaded by 1 of 5 different methods, then matured for 48 hours. Total cellular RNA was then extracted from 9 unloaded DC populations, 10 mRNA-loaded populations, 11 lysate-loaded populations, 7 doubly-loaded (matched) populations, and 7 doubly-loaded (mismatched) populations, a total of 44 different experiments. Each population was derived from a different normal human donor. Matched/mismatched refers to the source of the mRNA and lysate used to load the DCs. Matched signifies that the mRNA and lysate came from the same source. Mismatched signifies that the mRNA and lysate came from disparate sources. Gene expression profiles were then determined according to the method by which the DCs had been loaded. Genes were identified as differentially expressed by DCs doubly-loaded with matched antigens, only if they were significantly different from all of the other four controls. Significance was defined as Cohenâ??s |d| > 1.0 (large effect) and q-value (Benjamini-Hochberg false discovery) < 0.01.

2008-06-15 | E-GEOD-7247 | biostudies-arrayexpress

A multi-adjuvant nanovaccine platform based on targeted delivery of specific antigens for cancer immunotherapy

Project description:Cance vaccines have become a milestone in immunotherapy, but inadequate activation rate of antigen presenting cells (APCs) and low delivery efficiency of specific antigen have widely limited their clinical application. Here we design an engineered vaccine platform based on targeted delivery of specific antigens to activated APCs. This vaccine platform is implemented by loading stimulator of interferon genes agonist and tumor lysate protein with calcium phosphate as adjuvants, and coating the surface with mannose-modified liposomes. By loading different types of tumor antigen proteins, this nanovaccine platform successfully achieves tumor immunotherapy in breast and colon cancer bearing mice. In addition, personalized nanovaccine prepared from surgically removed tumor lysate proteins also significantly suppresses postsurgical distant tumor. Through the design of nanovaccine platform, we provide an efficient multi-adjuvant delivery platform for multiple types of tumor antigens, and also offer more ideas for personalized vaccine immunization. This nanovaccine platform has great prospects for transformation due to the designability and simplicity for the preparation.

2024-05-14 | GSE267162 | GEO

mRNA-based precision targeting of neoantigens and tumor-associated antigens in malignant brain tumors

Project description:mRNA-based immunotherapeutics have garnered widespread interest for their potential to revolutionize cancer treatment. In this study, we have established a personalized and customizable mRNA-therapeutic approach that effectively targets a plurality of tumor antigens and demonstrated potent anti-tumor response in preclinical brain tumor models. Our platform uniquely addresses the challenge of tumor heterogeneity and low antigen burden, two key deficiencies in targeting classically immunotherapy-resistant CNS malignancies.

2024-01-25 | GSE252247 | GEO

Noncoding regions are the main source of targetable tumor-specific antigens

Project description:Noncoding regions are the main source of targetable tumor-specific antigens

| PRJNA525590 | ENA

Non-coding regions are the main source of tumor-specific antigens

Project description:Non-coding regions are the main source of tumor-specific antigens

| PRJNA454807 | ENA